Axonics, Inc. (AXNX)
After hours:
| Previous close | 67.20 |
| Open | 67.34 |
| Bid | 48.35 x 100 |
| Ask | 85.92 x 100 |
| Day's range | 66.97 - 67.34 |
| 52-week range | 47.59 - 69.68 |
| Volume | |
| Avg. volume | 943,514 |
| Market cap | 3.42B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.12 |
| Earnings date | 29 Apr 2024 - 03 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 71.73 |
ZacksAll You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Business WireAxonics Stockholders Approve Merger Agreement with Boston Scientific
IRVINE, Calif., March 22, 2024--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independen
Business WireAxonics Provides Update on Inter Partes Review Proceedings
IRVINE, Calif., March 21, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.
